Physician profile
Seth E Hurwitz
NPI 1033369806
$2,979.16
in general payments reported to CMS, 2019-2025
28 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $281 · 2021: $280 · 2022: $173 · 2023: $165 · 2024: $324 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.59 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,018.73 | 2019-2025 | General - Therapies, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $182.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $177.76 | 2019-2025 | Farxiga |
| Pfizer INC. | $162.05 | 2019-2020 | |
| Medtronic, INC. | $159.98 | 2025 | Symplicity G3 |
| Bridgebio Pharma, INC. | $122.83 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $118.42 | 2022 | |
| Abiomed | $113.63 | 2019 | |
| Amarin Pharma, INC. | $99.37 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $98.99 | 2024 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $96.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $90.41 | 2019-2021 | |
| Irhythm Technologies, INC. | $77.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.64 | 2019-2022 | |
| Atricure, INC. | $53.25 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $41.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.84 | 2025 | |
| Bardy Diagnostics, INC. | $30.62 | 2020 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Lundbeck LLC | $20.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.37 | 2020 | |
| Portola Pharmaceuticals, LLC | $17.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.04 | 2019 | |
| Lilly USA, LLC | $13.98 | 2025 | Zepbound |
| Medtronic Vascular, INC. | $13.41 | 2019 | |
| Abbvie INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Hurwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.